-
1
-
-
84918804764
-
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
-
Solomon, B.J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167–2177 (2014).
-
(2014)
N. Engl. J. Med.
, vol.371
, pp. 2167-2177
-
-
Solomon, B.J.1
-
2
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
-
3
-
-
84872967522
-
Cancer statistics, 2013
-
Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11–30 (2013).
-
(2013)
CA Cancer J. Clin.
, vol.63
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
4
-
-
84866894408
-
Comprehensive genomic characterization of squamous cell lung cancers
-
Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489, 519–525 (2012).
-
(2012)
Nature
, vol.489
, pp. 519-525
-
-
-
5
-
-
84906851561
-
New clinical research strategies in thoracic oncology: Clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
-
Menis, J., Hasan, B. & Besse, B. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur. Respir. Rev. 23, 367–378 (2014).
-
(2014)
Eur. Respir. Rev.
, vol.23
, pp. 367-378
-
-
Menis, J.1
Hasan, B.2
Besse, B.3
-
6
-
-
79957857433
-
The BATTLE trial: Personalizing therapy for lung cancer
-
Kim, E.S. et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 1, 44–53 (2011).
-
(2011)
Cancer Discov
, vol.1
, pp. 44-53
-
-
Kim, E.S.1
-
7
-
-
84893362995
-
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
-
Champiat, S. et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J. Thorac. Oncol. 9, 144–153 (2014).
-
(2014)
J. Thorac. Oncol.
, vol.9
, pp. 144-153
-
-
Champiat, S.1
-
8
-
-
84937518516
-
Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: Metastatic non-small cell lung cancer
-
Ramalingam, S.S. et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 90, 1266–1267 (2014).
-
(2014)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.90
, pp. 1266-1267
-
-
Ramalingam, S.S.1
-
10
-
-
85138528304
-
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody
-
Segal, N. et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Chicago: ASCO.
-
Chicago: ASCO.
-
-
-
11
-
-
13944284494
-
Oncogenic mutations of PIK3CA in human cancers
-
Samuels, Y. & Velculescu, V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 3, 1221–1224 (2004).
-
(2004)
Cell Cycle
, vol.3
, pp. 1221-1224
-
-
Samuels, Y.1
Velculescu, V.E.2
-
12
-
-
8444240824
-
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression
-
Massion, P.P. et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit. Care Med. 170, 1088–1094 (2004).
-
(2004)
Am. J. Respir. Crit. Care Med.
, vol.170
, pp. 1088-1094
-
-
Massion, P.P.1
-
13
-
-
84879056371
-
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyra-zol-1-yl}-2-methylpropanamide (GDC-0032): A beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity
-
Ndubaku, C.O. et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyra-zol-1-yl}-2-methylpropanamide (GDC-0032): A beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J. Med. Chem. 56, 4597–4610 (2013).
-
(2013)
J. Med. Chem.
, vol.56
, pp. 4597-4610
-
-
Ndubaku, C.O.1
-
14
-
-
33645802169
-
Cyclin-dependent kinase pathways as targets for cancer treatment
-
Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1770-1783
-
-
Shapiro, G.I.1
-
15
-
-
84922369296
-
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study
-
Finn, R.S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015).
-
(2015)
Lancet Oncol
, vol.16
, pp. 25-35
-
-
Finn, R.S.1
-
16
-
-
84880695940
-
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
-
Dickson, M.A. et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J. Clin. Oncol. 31, 2024–2028 (2013).
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 2024-2028
-
-
Dickson, M.A.1
-
17
-
-
84860120185
-
AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
-
Gavine, P.R. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045–2056 (2012).
-
(2012)
Cancer Res
, vol.72
, pp. 2045-2056
-
-
Gavine, P.R.1
-
18
-
-
84871217393
-
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models
-
Zhang, J. et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin. Cancer Res. 18, 6658–6667 (2012).
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 6658-6667
-
-
Zhang, J.1
-
19
-
-
84937637414
-
A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data
-
Paik, P. et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. Clin Oncol 32, 5s, (2014).
-
(2014)
Clin Oncol
, vol.5s
, pp. 32
-
-
Paik, P.1
-
20
-
-
13944276728
-
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
-
Ma, P.C. et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479–1488 (2005).
-
(2005)
Cancer Res
, vol.65
, pp. 1479-1488
-
-
Ma, P.C.1
-
21
-
-
38649119730
-
Signaling networks assembled by oncogenic EGFR and c-Met
-
Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U. S. A. 105, 692–697 (2008).
-
(2008)
Proc. Natl. Acad. Sci. U. S. A.
, vol.105
, pp. 692-697
-
-
Guo, A.1
-
22
-
-
70349315347
-
Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs
-
Richey, E.A. et al. Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs, J. Clin. Oncol. 27, 4398–4405 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4398-4405
-
-
Richey, E.A.1
|